SCHEMBL1855074

SCHEMBL1855074

CC(C)(C)OC(=O)N1CCC(Oc2cc(C(=O)O)on2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 14/20 0.49
CACNB4 O00305 2/20 0.44
CACNA1A O00555 2/20 0.44
CACNA1G O43497 2/20 0.44
CACNG3 O60359 2/20 0.44
CACNA1F O60840 2/20 0.44
CACNA1H O95180 2/20 0.44
CACNB3 P54284 2/20 0.44
CACNA2D1 P54289 2/20 0.44
CACNG7 P62955 2/20 0.44
CACNA1B Q00975 2/20 0.44
CACNA1D Q01668 2/20 0.44
CACNB1 Q02641 2/20 0.44
CACNG1 Q06432 2/20 0.44
CACNB2 Q08289 2/20 0.44
CACNA1S Q13698 2/20 0.44
CACNA1C Q13936 2/20 0.44
CACNA1E Q15878 2/20 0.44
CACNA2D4 Q7Z3S7 2/20 0.44
CACNA2D3 Q8IZS8 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20150217 0.85 GPR119 (0.50) GPR119CACNB4CACNA1ACACNA1GCACNG3
SCHEMBL7372143 0.83 FAAH (0.46) GPR119USP30
SCHEMBL8618501 0.82 FAAH (0.48) GPR119USP30
SCHEMBL25263211 0.81 GPR119 (0.48) GPR119CACNB4CACNA1ACACNA1GCACNG3
SCHEMBL7446229 0.81 GPR119 (0.53) GPR119
SCHEMBL8617529 0.81 GPR119 (0.53) GPR119
SCHEMBL25899721 0.78 GPR119 (0.46) GPR119CACNB4CACNA1ACACNA1GCACNG3
SCHEMBL1853083 0.77 GPR119 (0.52) GPR119CACNB4CACNA1ACACNA1GCACNG3
SCHEMBL23512834 0.77 USP30 (0.51) GPR119USP30PDE4B
SCHEMBL17572116 0.76 GPR119 (0.53) GPR119CACNB4CACNA1ACACNA1GCACNG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 GPR119 545/4885CACNB4 423/4885CACNA1A 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.